WeVote
Log In

Bill

Bill

SB 374

Newborn screening requirements; includes Gaucher disease.

2026 Regular Session Introduced by Jennifer Boysko

SB 374 mandates Virginia newborn screening for Gaucher disease, enabling early treatment but raising questions about cost-effectiveness for detecting rare genetic conditions.

Senate committee offered
0
WeVote Research Nonpartisan
Bill Summary · SB 374

Legislative bill overview

SB 374 expands Virginia's mandatory newborn screening program to include Gaucher disease, a rare genetic disorder affecting enzyme function that causes organ damage and neurological complications. The bill requires all newborns to be tested for this condition before hospital discharge, adding it to the state's existing screening panel.

Why is this important

Early detection of Gaucher disease enables treatment before symptoms progress, potentially preventing severe disability or death. Currently, many cases go undiagnosed until irreversible organ damage occurs. However, adding screening tests increases healthcare costs and may identify rare conditions where treatment options are limited, raising questions about resource allocation in public health systems.

Potential points of contention

  • Cost-benefit analysis: Gaucher disease is extremely rare (1 in 40,000-60,000 births); critics may question whether screening costs justify detecting such a small number of cases
  • Treatment accessibility: Identifying newborns with Gaucher disease is only beneficial if families can access expensive enzyme replacement therapies, which cost $200,000+ annually and may not be covered by all insurance plans
  • Screening panel scope: This sets precedent for adding other rare genetic conditions, potentially expanding screening requirements indefinitely and straining laboratory capacity

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.